

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention

MTA1 IS A PREDICTIVE AND PROGNOSTIC FACTOR IN HUMAN BREAST CANCER

As the below named inventor(s), I/we declare that:

The declaration is directed to:

☐ The attached application, or

☒ Application No. 10/600,747, filed on 06/20/2003,

☐ as amended on _____ (if applicable).

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME(S) OF INVENTORS:

Inventor one: Michelle D. Martin

Signature: Michelle D. Martin Date: 9/1/03 Citizen of: US

Inventor two: Peter O'Connell

Signature: _____ Date: _____ Citizen of: US

Inventor three: D. C. Allred

Signature: _____ Date: _____ Citizen of: US

Inventor four: Gary Clark

Signature: _____ Date: _____ Citizen of: US


☐ Additional inventors are being named on _____ additional form(s) attached hereto.

Declaration for Utility or Design Patent Application

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147060217US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/26/04

Signature: Linda A. Bourg (Linda A. Bourg)



DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)	
Title of Invention	MTA1 IS A PREDICTIVE AND PROGNOSTIC FACTOR IN HUMAN BREAST CANCER
As the below named inventor(s), I/we declare that: The declaration is directed to: <input type="checkbox"/> The attached application, or <input checked="" type="checkbox"/> Application No. <u>10/600,747</u> , filed on <u>06/20/2003</u> , <input type="checkbox"/> as amended on _____ (if applicable). I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	

FULL NAME(S) OF INVENTORS:			
Inventor one:	<u>Michelle D. Martin</u>		
Signature:	Date:	Citizen of:	<u>US</u>
Inventor two:	<u>Peter O'Connell</u>		
Signature: <u>Peter O'Connell</u>	Date: <u>2/24/04</u>	Citizen of:	<u>US</u>
Inventor three:	<u>D. C. Allred</u>		
Signature:	Date:	Citizen of:	<u>US</u>
Inventor four:	<u>Gary Clark</u>		
Signature:	Date:	Citizen of:	<u>US</u>
<input type="checkbox"/> Additional inventors are being named on _____ additional form(s) attached hereto.			

Declaration for Utility or Design Patent Application	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147060217US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>2/26/04</u>	Signature: <u>Linda A. Bourg</u> (Linda A. Bourg)



**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	MTA1 IS A PREDICTIVE AND PROGNOSTIC FACTOR IN HUMAN BREAST CANCER
---------------------------	--

As the below named inventor(s), I/we declare that:

The declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/600,747, filed on 06/20/2003,
- ☐ as amended on _____ (if applicable).

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME(S) OF INVENTORS:

Inventor one: Michelle D. Martin

Signature: _____ Date: _____ Citizen of: US

Inventor two: Peter O'Connell

Signature: _____ Date: _____ Citizen of: US

Inventor three: D. C. Allred

Signature: [Signature] Date: 8.26.03 Citizen of: US

Inventor four: Gary Clark

Signature: _____ Date: _____ Citizen of: US


☐ Additional inventors are being named on _____ additional form(s) attached hereto.

Declaration for Utility or Design Patent Application

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147060217US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/26/04

Signature: Linda A. Bourg (Linda A. Bourg)



**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention

MTA1 IS A PREDICTIVE AND PROGNOSTIC FACTOR IN HUMAN BREAST
CANCER

As the below named inventor(s), I/we declare that:

The declaration is directed to:

☐ The attached application, or

☒ Application No. 10/600,747, filed on 06/20/2003,

☐ as amended on _____ (if applicable).

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME(S) OF INVENTORS:

Inventor one: Michelle D. Martin

Signature: _____ Date: _____ Citizen of: US

Inventor two: Peter O'Connell

Signature: _____ Date: _____ Citizen of: US

Inventor three: D. C. Allred

Signature: _____ Date: _____ Citizen of: US

Inventor four: Gary Clark

Signature: Gary Clark Date: 20 Oct 2003 Citizen of: US

☐ Additional inventors are being named on _____ additional form(s) attached hereto.

Declaration for Utility or Design Patent Application

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147060217US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/26/04

Signature: Linda A. Bourg (Linda A. Bourg)


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147060217US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/26/04

Signature:

Linda Bourg
(Linda Bourg)

Docket No.: HO-P02483US1
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michelle D. Martin, et al.

Application No.: 10/600,747

Filed: June 20, 2003

Art Unit: N/A

For: MTA1 IS A PREDICTIVE AND PROGNOSTIC
FACTOR IN HUMAN BREAST CANCER

POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Baylor College of Medicine, assignee of the entire right, title and interest in the above-identified application by assignment submitted herewith, hereby appoints the following attorneys and/or agents of the firm of Fulbright & Jaworski L.L.P.:

All practioners at Customer Number 26271.

as its attorneys with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

The assignee certifies that it has reviewed the assignment and to the best of the assignee's knowledge and belief, title is in the assignee.

Please direct all correspondence regarding this application to the following:

Application No.: 10/600,747

Docket No.: HO-P02483US1

FULBRIGHT & JAWORSKI L.L.P.

Attn: Jila Bakker


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

Telephone: (713) 651-5151

Fax: (713) 651-5246

For: Baylor College of Medicine



W. Dalton Tomlin

Dated: _____

